Artificial Cell Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Artificial Cell Technologies is pioneering a novel, fully synthetic vaccine manufacturing platform using Layer-by-Layer (LbL) polypeptide nanofilms. This technology aims to produce temperature-stable, multi-valent vaccines rapidly and at low cost, enabling decentralized production closer to patient populations. The company's initial pipeline targets Respiratory Syncytial Virus (RSV) and malaria, with a malaria vaccine candidate historically noted as preparing for Phase 1 trials. ACT's approach seeks to disrupt traditional vaccine supply chains, particularly for the developing world.

Infectious Disease

Technology Platform

Proprietary Layer-by-Layer (LbL) assembly process to create ultra-thin multilayer polypeptide nanofilms for fully synthetic, temperature-stable vaccine antigen delivery.

Opportunities

The platform targets the massive need for low-cost, temperature-stable, and rapidly manufacturable vaccines in developing countries, addressing critical gaps in global health equity.

Its synthetic, decentralized production model could also be highly valuable for pandemic preparedness and rapid response to emerging pathogens.

Risk Factors

The company faces high technical risk with an unproven, novel vaccine platform and significant regulatory uncertainty.

As a pre-revenue, pre-clinical company, it is dependent on raising substantial capital in a competitive funding environment to advance its programs.

Competitive Landscape

ACT competes with large vaccine manufacturers (GSK, Pfizer, Merck) and biotechs developing novel platforms (mRNA, viral vectors) for malaria and RSV. Its differentiation hinges on achieving superior cost, stability, and decentralized manufacturing advantages, which are not yet proven.

More companies in Synthetic Biology →More companies in United States →